Lead Product(s): Mazindol
Therapeutic Area: Psychiatry/Psychology Product Name: Quilience
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: NLS Pharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2021
Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, used for to treat narcolepsy in compassionate use programs.